Robinhood, Applovin jump as S&P 500 reshuffle boosts index entrants
Investing.com -- Hoth Therapeutics Inc (NASDAQ:HOTH) stock surged 12.5% after the clinical-stage biopharmaceutical company announced positive preclinical results for its precision antisense candidate HT-KIT.
The company reported that HT-KIT demonstrated significant anti-tumor efficacy in preclinical models, with tumor cell death observed as early as 24 hours after treatment and statistically significant tumor shrinkage by day 8. The drug candidate achieved over 80% knockdown of KIT expression, which is an oncogenic driver in multiple aggressive cancers.
Safety studies showed no off-target toxicity across critical organs including liver, kidneys, spleen, bone marrow, and thymus. The bioanalytical results, conducted under Good Laboratory Practice (GLP) standards by Altasciences Company, Inc., met or exceeded regulatory benchmarks with 90.5% of Incurred Sample Reanalysis values falling within ±30%, above the 66.7% regulatory minimum.
"These results combine a rare and powerful story — tumor kill within 24 hours, clean safety across all systems, and GLP-validated reproducibility beyond regulatory standards," said Robb Knie, CEO of Hoth Therapeutics .
The company plans to integrate the bioanalytical data into its formal GLP toxicology package as it prepares for an Investigational New Drug (IND) submission, which would allow for first-in-human clinical trials.
Hoth Therapeutics is developing HT-KIT for potential treatment of gastrointestinal stromal tumors and systemic mastocytosis, both KIT-driven cancers.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.